Seroprevalence of Human Papilloma Virus 6, 11, 16 and 18 Among Pregnant Women in Mwanza-Tanzania

Overview

Journal Infect Agent Cancer

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Oct 8

PMID 39380040

Authors

Fridolin Mujuni

Betrand Msemwa

Vicent E Fukuru

Vitus Silago

Mariam M Mirambo

Stephen E Mshana

Balthazar Gumodoka

Affiliations

Soon will be listed here.

Abstract

Introduction: High-risk human-papilloma viruses 16 and 18 (HR-HPV 16 and HR-HPV-18) are well known to be associated with carcinoma of the cervix, head and neck, penis, and anus. Low-risk human papillomaviruses 6 and 11 (LR-HPV 6 and LR 11) infection has been associated with anogenital warts, oral papilloma, and laryngeal papillomatosis in children. HPV infection during pregnancy (HR-HPV and LR-HPV) increases the risk of vertical transmission from infected pregnant women to unborn children. The burden of HR-HPV type 16 and 18 and LR-HPV 6 and 11 is not well documented among pregnant women attending antenatal clinics (ANC). This study determined the seroprevalence and distributions of HR-HPV 16, 18, and LR -HPV 6, 11 antibodies among pregnant women attending ANC at Bugando Medical Centre (BMC) in Mwanza, Tanzania.

Methodology: A cross-sectional study involving 255 pregnant women enrolled in obstetrics and gynecology outpatient clinics was conducted between November 2020 and March 2021 at Bugando Medical Centre (BMC) in Mwanza. A structured pre-tested questionnaire was used to obtain patients' information. Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect HPV 6, 11, 16 and 18 specific immunoglobulin G (IgG) from sera. Stata version 15v1 was used for the descriptive data analysis.

Results: The median age was 27(IQR: 22-31) years. The overall HPV seropositivity for any of the four serotypes was 63.9% (165/255), 95% CI: 58.0-69.7, whereby 37.6%(97/255), 32.2%( 83/255), 15.5% (40/255) and 27.1% (70) were positive for HPV 6, 11, 16 and 18 respectively. Eight participants (3.1%) were positive for all 4 genotypes.

Conclusion: About two-thirds of pregnant women had antibodies against HPV 6, 11 16, and 18 indicating previous HPV exposure. Vaccination programs should be emphasized to reduce the HPV-related manifestations in this population.

References

Clifford G, Franceschi S, Diaz M, Munoz N, Villa L . Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24 Suppl 3:S3/26-34. DOI: 10.1016/j.vaccine.2006.05.026. View

Bedoya A, Gaviria A, Baena A, Borrero M, Duarte D, Combita A . Age-specific seroprevalence of human papillomavirus 16, 18, 31, and 58 in women of a rural town of Colombia. Int J Gynecol Cancer. 2012; 22(2):303-10. DOI: 10.1097/IGC.0b013e31823c2469. View

Lewis R, Markowitz L, Gargano J, Steinau M, Unger E . Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14-59 Years, United States, 2013-2014. J Infect Dis. 2018; 217(6):869-877. PMC: 5991084. DOI: 10.1093/infdis/jix655. View

Nicol A, Grinsztejn B, Friedman R, Veloso V, Cunha C, Georg I . Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil. J Clin Virol. 2013; 57(2):147-51. DOI: 10.1016/j.jcv.2013.02.007. View

Koutsky L . Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102(5A):3-8. DOI: 10.1016/s0002-9343(97)00177-0. View

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

Banura C, Franceschi S, van Doorn L, Arslan A, Wabwire-Mangen F, Mbidde E . Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis. 2008; 197(4):555-62. DOI: 10.1086/526792. View

Marais D, Sampson C, Urban M, Sitas F, Wiliamson A . The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children. J Med Virol. 2007; 79(9):1370-4. DOI: 10.1002/jmv.20874. View

Castle P, Shields T, Kirnbauer R, Manos M, Burk R, Glass A . Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis. 2002; 29(3):182-7. DOI: 10.1097/00007435-200203000-00009. View

10.

Ji J, Sun H, Smith J, Wang H, Esser M, Hu S . Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women. BMC Infect Dis. 2012; 12:137. PMC: 3482566. DOI: 10.1186/1471-2334-12-137. View

11.

Firnhaber C, Evans D, Friedman-Khalili R, Willliams S, Michelow P, Matlhagela K . Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana. J Clin Virol. 2011; 52(3):265-8. DOI: 10.1016/j.jcv.2011.08.011. View

12.

Lu B, Viscidi R, Lee J, Wu Y, Villa L, Lazcano-Ponce E . Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev. 2011; 20(5):990-1002. PMC: 3232028. DOI: 10.1158/1055-9965.EPI-10-1160. View

13.

Bakari F, Abdul M, Ahmed S . The prevalence and course of preinvasive cervical lesions during pregnancy in a Northern Nigerian Teaching Hospital. Ann Afr Med. 2017; 16(2):74-80. PMC: 5452714. DOI: 10.4103/aam.aam_35_16. View

14.

Brandao V, Lacerda H, Lucena-Silva N, Ximenes R . Frequency and types of human papillomavirus among pregnant and non-pregnant women with human immunodeficiency virus infection in Recife determined by genotyping. Mem Inst Oswaldo Cruz. 2009; 104(5):755-63. DOI: 10.1590/s0074-02762009000500016. View

15.

Dames D, Blackman E, Butler R, Taioli E, Eckstein S, Devarajan K . High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas. PLoS One. 2014; 9(1):e85429. PMC: 3900425. DOI: 10.1371/journal.pone.0085429. View

16.

Carter J, Koutsky L, Hughes J, Lee S, Kuypers J, Kiviat N . Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000; 181(6):1911-9. DOI: 10.1086/315498. View

17.

Ogembo R, Gona P, Seymour A, Park H, Bain P, Maranda L . Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis. PLoS One. 2015; 10(4):e0122488. PMC: 4396854. DOI: 10.1371/journal.pone.0122488. View

18.

Lacey C, Lowndes C, Shah K . Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006; 24 Suppl 3:S3/35-41. DOI: 10.1016/j.vaccine.2006.06.015. View

19.

Rama C, Villa L, Pagliusi S, Andreoli M, Costa M, Thomann P . Seroprevalence of human papillomavirus 6, 11, 16, and 18 in young primiparous women in Sao Paulo, Brazil. Int J Gynecol Cancer. 2010; 20(8):1405-10. DOI: 10.1111/IGC.0b013e3181f3c85e. View